Propyl-2-(8-(3,4-Difluorobenzyl)-2′,5′-Dioxo-8-Azaspiro[Bicyclo[3.2.1] Octane-3,4′-Imidazolidine]-1′-yl) Acetate Induces Apoptosis in Human Leukemia Cells through Mitochondrial Pathway following Cell Cycle Arrest

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Kavitha, Chandagirikoppal V ^a   Nambiar, Mridula ^a   Narayanaswamy, Pavan B ^a   Thomas, Elizabeth ^a   Rathore, Ujjwal ^a   Ananda Kumar, Channapillekoppalu S ^b   Choudhary, Bibha ^a   Rangappa, Kanchugarakoppal S ^b   Raghavan, Sathees C ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b UNIVERSITY OF MYSORE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; HYDANTOIN DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLSERINE; PROPYL 2 [8 (3,4 DIFLUOROBENZYL) 2',5' DIOXO 8 AZASPIRO[BICYCLO[3.2.1]OCTANE 3,4' IMIDAZOLIDINE] 1' YL]ACETIC ACID; PROTEIN BAD; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; BIOLOGICAL TRANSPORT; CASPASE INHIBITORS; CELL CYCLE CHECKPOINTS; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; DNA BREAKS; DNA REPAIR ENZYMES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDANTOINS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; K562 CELLS; LEUKEMIA; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MODELS, BIOLOGICAL; PHOSPHATIDYLSERINES; SIGNAL TRANSDUCTION; SPIRO COMPOUNDS; TIME FACTORS;

EID: 84880792177     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069103     Document Type: Article

References (25)

1. Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA, (2003) Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 97: 2229-2235.
2. Sedletska Y, Giraud-Panis MJ, Malinge JM, (2005) Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 5: 251-265.
3. Neuzil J, Dyason JC, Freeman R, Dong LF, Prochazka L, et al. (2007) Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. J Bioenerg Biomembr 39: 65-72.
4. Nefzi A, Giulianotti M, Truong L, Rattan S, Ostresh JM, et al. (2002) Solid-phase synthesis of linear ureas tethered to hydantoins and thiohydantoins. J Comb Chem 4: 175-178.
5. Bazil CW, Pedley TA, (1998) Advances in the medical treatment of epilepsy. Annu Rev Med 49: 135-162.
6. Thenmozhiyal JC, Wong PT, Chui WK, (2004) Anticonvulsant activity of phenylmethylenehydantoins: a structure-activity relationship study. J Med Chem 47: 1527-1535.
7. Rodgers TR, LaMontagne MP, Markovac A, Ash AB, (1977) Hydantoins as antitumor agents. J Med Chem 20: 591-594.
8. Comber RN, Reynolds RC, Friedrich JD, Manguikian RA, Buckheit RW Jr, et al. (1992) 5,5-disubstituted hydantoins: syntheses and anti-HIV activity. J Med Chem 35: 3567-3572.
9. Tompkins JE, (1986) 5,5-Diaryl-2-thiohydantoins and 5,5-diaryl-N3-substituted-2-thiohydantoins as potential hypolipidemic agents. J Med Chem 29: 855-859.
10. Somsak L, Kovacs L, Toth M, Osz E, Szilagyi L, et al. (2001) Synthesis of and a comparative study on the inhibition of muscle and liver glycogen phosphorylases by epimeric pairs of d-gluco- and d-xylopyranosylidene-spiro-(thio)hydantoins and N-(d-glucopyranosyl) amides. J Med Chem 44: 2843-2848.
11. Kavitha CV, Nambiar M, Ananda Kumar CS, Choudhary B, Muniyappa K, et al. (2009) Novel derivatives of spirohydantoin induce growth inhibition followed by apoptosis in leukemia cells. Biochem Pharmacol 77: 348-363.
12. Fiallo MM, Kozlowski H, Garnier-Suillerot A, (2001) Mitomycin antitumor compounds. Part 1. CD studies on their molecular structure. Eur J Pharm Sci 12: 487-494.
13. Ananda Kumar CS, Kavitha CV, Vinaya K, Benaka Prasad SB, Thimmegowda NR, et al. (2009) Synthesis and in vitro cytotoxic evaluation of novel diazaspiro bicyclo hydantoin derivatives in human leukemia cells: a SAR study. Invest New Drugs 27: 327-337.
14. Rosenfeld C, Goutner A, Venuat AM, Choquet C, Pico JL, et al. (1977) An effect human leukaemic cell line: Reh. Eur J Cancer 13: 377-379.
15. Shahabuddin MS, Nambiar M, Choudhary B, Advirao GM, Raghavan SC, (2010) A novel DNA intercalator, butylamino-pyrimido[4′,5′:4,5]selenolo(2,3-b)quinoline, induces cell cycle arrest and apoptosis in leukemic cells. Invest New Drugs 28: 35-48.
16. Shahabuddin MS, Nambiar M, Moorthy BT, Naik PL, Choudhary B, et al. (2011) A novel structural derivative of natural alkaloid ellipticine, MDPSQ, induces necrosis in leukemic cells. Invest New Drugs 29: 523-533.
17. Chiruvella KK, Kari V, Choudhary B, Nambiar M, Ghanta RG, et al. (2008) Methyl angolensate, a natural tetranortriterpenoid induces intrinsic apoptotic pathway in leukemic cells. FEBS Lett 582: 4066-4076.
18. Miyato Y, Ando K, (2004) Apoptosis of human melanoma cells by a combination of lonidamine and radiation. J Radiat Res (Tokyo) 45: 189-194.
19. Kumar TS, Kari V, Choudhary B, Nambiar M, Akila TS, et al. (2010) Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells. J Biol Chem 285: 32657-32670.
20. Lubbert M, Miller CW, Crawford L, Koeffler HP, (1988) p53 in chronic myelogenous leukemia. Study of mechanisms of differential expression. J Exp Med 167: 873-886.
21. Durland-Busbice S, Reisman D, (2002) Lack of p53 expression in human myeloid leukemias is not due to mutations in transcriptional regulatory regions of the gene. Leukemia 16: 2165-2167.
22. Rudin CM, Thompson CB, (1997) Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med 48: 267-281.
23. Shangary S, Ohver CL, Johnson DE (2005) Mitochondrial death pathway and new cancer therapeutics: bcl-2 family in focus.; Gibson L, editor: Springer.
24. Thornberry NA, Lazebnik Y, (1998) Caspases: enemies within. Science 281: 1312-1316.
25. Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, et al. (1997) Substrate specificities of caspase family proteases. J Biol Chem 272: 9677-9682.